ProCE Banner Activity

Optimizing Use of BTK Inhibitors in CLL/SLL and MCL for Managed Care Professionals


Download these slides from a live webinar to learn more about the latest data supporting the efficacy and safety of BTK inhibitor–based therapeutic approaches for patients with CLL/SLL or MCL, including strategies to promote equitable, cost-effective, and evidence-based care for patients with these diseases.

Released: January 11, 2024



Donald C. Moore

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP

Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer Institute
Charlotte, North Carolina

Victoria Nachar

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Provided by

Provided by ProCE, LLC

ProCE Banner


This activity is supported by an educational grant from Lilly.